The Shiu Laboratory

Chronic Kidney Disease (CKD) affects 10% of the population worldwide. It is characterized by a gradual loss of kidney function over time and can progress to end-stage kidney disease (ESKD), at which point most U.S. patients rely on hemodialysis to survive. The average life expectancy for dialysis patients in the U.S. is about 5 to 10 years, and cardiovascular disease (CVD) is a leading comorbidity and cause of death in this population.

The Shiu Lab (Vascular Access & Health Laboratory) integrates medicine, engineering, and bioscience to investigate the pathophysiology of hemodialysis vascular access dysfunction and the progression of CVD in individuals with CKD. Guided by a Bedside-to-Bench-to-Bedside philosophy, we begin with clinical observations and translate them into mechanistic animal (pig, rat, mouse) and cell studies, then bring discoveries back to patients.

Our unique database of blood-flow imaging and computational simulations of arteriovenous accesses allows us to investigate hemodynamics and mechanotransduction in vascular cells, deepen fundamental insight, and inform the design of targeted therapies. By prolonging access longevity, restoring vascular function, and curbing CVD progression, we aim to measurably improve the quality of life for people living with CKD. Given that CVD is the leading cause of death in this population, our research also seeks to uncover the intricate mechanisms linking vascular dysfunction, CKD and CVD, ultimately striving to improve outcomes for individuals affected by these interrelated conditions.